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Objective: The aim of this study is to develop a simple and efficient
screening questionnaire to be able to routinely monitor potential radioiodine
therapy-induced complications.
Materials and Methods: A new radioiodine 6 (RAI-6) questionnaire containing six
questions adressing salivary, ocular, and nasal symptoms as well as quality of life was
developed. Validation of the RAI-6 questionnaire was assessed with a group of fifty-four
patients diagnosed with differentiated thyroid carcinoma treated post-operatively with
radioiodine therapy, and in a group of fifty healthy volunteers. The patient’s group was
subdivided into subgroups according to the radioiodine dose received: 23 patients
received less or 30 mCi, 28 patients received 100 mCi, and three patients received
between 200 and 300mCi. We asked the patients to complete the RAI-6 questionnaire in
a retrospective manner, regarding their situation before radioiodine therapy and regarding
their actual symptoms after radioiodine therapy. The time needed to complete the RAI-6
was also assessed both in patients and in healthy volunteers.
Results: The mean post radioiodine treatment RAI-6 score were significantly higher
than the mean pre radioiodine RAI-6 scores (p < 0.001) and the scores of healthy
participants (p < 0.001). The mean total RAI-6 scores increased significantly with
increasing radioiodine dose. A total mean RAI-6 score of each question was also
analysed and revealed that ocular and nasal discomfort as well as quality of life were
the items which affected the patients most after radioiodine treatment. The mean time
to fill the RAI-6 questionnaire was 2min for patients and 49 s for healthy volunteers.
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Conclusion: The RAI-6 represents a new questionnaire which is easy and quick to
complete. This simple screening tool can be recommended for general clinical practise
and further epidemiological research.
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INTRODUCTION
Thyroid carcinoma is the most common endocrine malignancy,
ranking in ninth place for cancer incidence worldwide (1). The
common histological types, papillary and follicular carcinoma,
are broadly classified as well-differentiated thyroid carcinoma
(2). Generally, a multimodality treatment approach is adopted
for these tumours consisting of total thyroidectomy followed by
radioiodine treatment (2, 3). The most common adverse effects
of radioiodine treatment are xerostomia, sialadenitis, dry eyes,
dry nose, and dysgeusia (4–7) with either acute onset after a
therapeutic dose of radioactive iodine, or chronic onset with
progressive intensity lasting over months or years. The incidence
of acute sialadenitis is reported to be 24–67% whereas chronic
sialadenitis occurs in 11 to 43% (4). The diagnosis of radioiodine-
induced sialadenitis (RAIS) is clinical, essentially depending
on the patient’s complaints (5). Unfortunately, RAIS may be
frequently missed because these symptoms are not investigated
by clinicians, especially if they do not appear shortly after the
radioiodine treatment. Xerostomia usually appears 3 months to 1
year after the radioiodine treatment in 15 to 54% of patients (8, 9).
There are only a few retrospective studies regarding nasolacrimal
complications of radioiodine therapy (6); Jonklass et al. reported
that nasal and lacrimal dysfunction occurs in ∼10% of patients,
after a mean dose of 109 mCi of radioiodine. Even though
salivary side effects of radioiodine decrease many years after the
radioiodine treatment, Le Roux et al. still found a high rate of
xerostomia (31.9%) 6 years after the radioiodine treatment, as
well as 14% of their patients also experiencing salivary glands
swellings (10). Patients still experiencing symptoms more than
1 year after the radioiodine treatment are at high risk to present
permanent salivary and lacrymal glands damages (11). However,
patients treated with low radioiodine dose (30 mCi or less)
are very unlikely to experience long lasting complications [REF
idem] (7). Patients are usually recommended to drink two to
three litters of water every 24 h during the following days after the
radioiodine (RAI) treatment to allow the radioiodine excretion
of the salivary glands. Although investigated in the literature, the
use of lemon juice to reduce potential complications has no effect
and may even increase the damage to the salivary glands (12).
The high variability in the incidence of radioiodine
complications, especially regarding xerostomia and sialadenitis,
suggests a lack of standardisation regarding the methods used
to evaluate these symptoms and a potential underestimation of
these alterations in some studies. Also, regarding the literature no
consensus evaluation method exist, as nine studies were found
to use questionnaires to evaluate radioiodine complications;
however each study used a different questionnaire, either
custom-made or already existing xerostomia questionnaires
(13–21). Therefore, we strongly believe that there is a need for a
simple tool enabling a rapid assessment of radioiodine potential
adverse effects pre- and post-radioiodine therapy allowing to
compare the scores of each patient before and after treatment.
Here, we present a new 6-item questionnaire, called RAI-6,
as well as its validation with a retrospective cohort of thyroid
carcinoma patients having received radioiodine therapy and a
group of control healthy patients.
METHODS
The radioiodine 6 (RAI-6) is a six-item questionnaire using a
visual analogue scale with a 0 to 10 scoring (Table 1), where “0”
indicates the complete absence of symptoms and “10” indicates
its maximum severity. The first three questions assess patient’s
subjective feeling of dryness of the mouth and discomfort of the
eyes and nose. The next two questions concern the frequency of
tightness and swelling of the salivary glands. The last question
evaluates the quality of life in relation to those symptoms.
The 6 items of the RAI-6 were based on the radioiodine
complications described in the literature (4–7).
A retrospective study was conducted after obtaining the
ethical approval from the institutional ethical committee
(reference number 2019-00253). The study consisted of two
groups of participants: the first group included adult patients
with well-differentiated thyroid carcinoma already treated with
radioactive iodine therapy and the second group was composed
of healthy volunteers. Informed consent was obtained from
all participants. The group of patients already treated with
radioactive iodine were asked to complete the RAI-6 regarding
their actual symptoms and also regarding their initial state,
before undergoing the radioiodine treatment. The mean time
between radioiodine treatment and the assessment of the RAI-6
questionnaire was 3.6 years (±1.4 years). Participants previously
treated with chemotherapy and/or radiotherapy for other head
and neck cancers, as well as those presenting xerostomia due
to systemic disorders such as Sjögren’s syndrome or linked to
medications (c.f. anticholinergics, antihistamines) were excluded
from the study.
The patients were contacted to complete the questionnaire
either by phone or during an out-patient consultation. The time
needed to complete the questionnaire and the score results were
assessed and compared for statistical significance using a two-
tailed Fisher F test (Microsoft Excel 365 with XLSTAT365 add-
on) between patients pre- and post-radioiodine treatment and
between the two study groups.
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TABLE 1 | RAI-6 questionnaire (0–10 visual analogue scale).
1. Evaluate the dryness of your mouth
(None) 0 1 2 3 4 5 6 7 8 9 10 (Unbearable)
2. Evaluate the discomfort of your eyes
(None) 0 1 2 3 4 5 6 7 8 9 10 (Unbearable)
3. Evaluate the discomfort of your nose
(None) 0 1 2 3 4 5 6 7 8 9 10 (Unbearable)
4. Evaluate the frequency of itching and/or tightness of your salivary glands (in
front of the ears/below the lower jaw)
Never 0 1 2 3 4 5 6 7 8 9 10 (continuous)
5. Evaluate the frequency of swelling of your salivary glands (in front of the
ears/below the lower jaw)
(Never) 0 1 2 3 4 5 6 7 8 9 10 (continuous)
6. Evaluate your overall quality of life related to those symptoms
(No impact) 0 1 2 3 4 5 6 7 8 9 10 (severe impact)
RESULTS
The results regarding the participants demographics and time
to complete the RAI-6 are detailed in Table 2. Fifty healthy
volunteers and 54 patients fulfilled the inclusion criteria were
included in our study. In the patient’s group, 33 patients
(61.1%) were females and 21 (32%) were males. The age
varied from 30 to 90 years with a mean of 56.2 years. The
time needed to complete the RAI-6 questionnaire amounted
to 2min (50–180”). Most of the patients underwent total
thyroidectomy for papillary carcinoma (41/54 patients, 76%),
follicular carcinoma (5/54 patients, 9.2%) or undifferentiated
thyroid carcinoma (1/54 patients, 1.8%). Seven other patients
(13%) underwent radioiodine therapy either for Gravers diseases,
or for an autonomous nodule accompanied by hyperthyroidism.
Radioactive iodine therapy was administered with a dose varying
from 4.86 to 300 millicuries (mCi). Twenty-three patients
received 30 mCi or less, 28 patients received 100 mCi, and three
patients received between 200 and 300 mCi. The mean total RAI-
6 score amounted 1.7 before radioiodine treatment and 7.6 after
radioiodine treatment, a statistically significant difference (p <
0.001) (Table 3).
The 23 patients receiving 30 mCi or less had a RAI-6 total
mean score of 1.32 prior to-radioiodine and 7.48 after radioiodine
therapy (p < 0.001). In the sub-group who received 100 mCi of
radioiodine dose the pre- and post-treatment mean RAI-6 total
score were 1.8 and 6.4, respectively (p < 0.001). Finally, the three
patients receiving between 200 and 300 mCi, the mean RAI-6
total score was 3.7 before and 19.2 after radioiodine therapy (p
= 0.32) (Table 3).
The mean pre- and post-radioiodine treatment RAI-6 scores
were also analysed separately for each item (Q1, Q2, Q3, Q4+Q5,
and Q6) regarding every subgroup of patients depending on
their radioiodine dose (<or = 30, 100, 200–300 mCi) and the
results are detailed in Tables 4–6. The items 5 and 6 were
analysed together as they both assess sialadenitis symptoms.
Items regarding ocular and nasal dryness as well as quality of life
were those who were mostly worsened by radioiodine therapy,
increasing with the dose.






Total (n) 50 54
Age 37.98 56.2
Male 16 (32%) 21 (38.9%)
Female 34 (68%) 33 (61.1%)
Papillary thyroid carcinoma 0 41 (76%)
Follicular thyroid carcinoma 0 5 (9.2%)
Undifferentiated thyroid carcinoma 0 1 (1.8%)
Other (Gravers Disease, autonomous
nodule with hyperthyreoditis)
0 7 (13%)




Regarding the group of healthy volunteers, the mean age
was 38 years old and 34 patients (68%) were females and 16
(32%) were males. The mean time for healthy volunteers to
complete the RAI-6 was 49 s (12–120”) (Table 2 None of the
healthy participants addressed sialadenitis symptoms. The mean
total score for every other item remained under 0.5 (Table 7).
The mean total RAI-6 score for healthy participants significantly
differed from the post-treatment RAI-6 values of patients who
underwent radioiodine therapy (p < 0.001).
DISCUSSION
Regarding the literature, 10 studies used questionnaires to
evaluate the complications of radioiodine therapy. Seven of these
studies utilised a custom-made questionnaire. Regarding the last
three studies, Bhayani et al. (19) and Klein Hesselink et al. (20)
used the Quality-of-Life Xerostomia Questionnaire (QOLXQ)
and the Xerostomia Inventory, respectively. The last study by
Hollingsworth et al. (21) used modified questions from another
questionnaire previously validated with patients who underwent
external beam radiation therapy.
Our new screening questionnaire RAI-6 attempts to assess
the complications of radioiodine therapy, especially salivary
gland dysfunction, oral dryness, ocular and nasal discomfort,
and their influence on the quality of life. To validate the
RAI-6 questionnaire we compared the total scores between
healthy participants and patients who underwent radioiodine
therapy as well as the scores pre- and post-radioiodine therapy
between those same patients. Moreover, the time to complete
the RAI-6 questionnaire was also assessed and compared
between healthy volunteers and patients who had undergone
radioiodine treatment.
The total mean RAI-6 score was significantly higher in
patients treated with radioiodine (7.6) compared to healthy
volunteers (1.16). Also, the mean RAI-6 scores were higher
in patients after their radioiodine treatment (7.6) compared to
their RAI-6 mean total scores before RAI-6 therapy (1.7). The
total mean RAI-6 score of patients before radioiodine therapy is
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TABLE 3 | Healthy volunteers RAI-6 scores and pre- and post-radioiodine therapy patient’s mean RAI-6 scores according to the radioiodine dose received.
Number of
patients
mCi Mean pre radioiodine
treatment RAI-6 total score
Mean post radioiodine
treatment RAI-6 total score
p-value (comparison of mean
RAI-6 total scores between
pre- and post-radioiodine
treatment)
Healthy 50 0 1.16 –
Patients 54 All 1.7 7.6 <0.001
Patients 23 <or = 30 1.32 7.48 <0.001
Patients 28 100 1.8 6.4 <0.001
Patients 3 200–300 3.7 19.2 0.319
slightly higher (1.7) than the one of healthy participants (1.16).
We attribute this discrepancy to the high difference of the mean
ages between these two groups as the patient’s group was almost
20 years older.
Increasingly higher mean RAI-6 scores are found when
the administered radioiodine dose is 200–300 mCi (19.2) in
comparison to a dose of <or = to 30 mCi (7.48). Given the
assumption that the higher radioiodine doses are associated
with an increased symptoms, we can conclude that the RAI-6
questionnaire assesses well the severity of symptoms. However,
the RAI-6 scores of patients who received 100mCi (6.4) are lower
than those of patients who received 30 mCi (7.48). We believe
that this result may be biassed, and linked to the retrospective
nature of our study and the limited number of patients.
Regarding the first RAI-6 question evaluating xerostomia, the
post radioiodine mean score of patients interestingly increased in
a highermanner in patients who received lower radioiodine doses
compared to those who received higher radioiodine doses. No
rational explanation can be deducted, although this result may
be linked to the bias of our limited number of patients.
The second question, by addressing ocular discomfort in
a general manner, aims to include several ocular symptoms
such as epiphora, xerophthalmia, and recurrent or chronic
conjunctivitis. Ocular dryness is a relatively frequent adverse
effect of radioiodine therapy and its’ associated problems tend to
persist for a prolonged period after the end of the treatment (22).
The mean post radioiodine treatment RAI-6 scores regarding
the second question were higher than the pre-treatment mean
RAI-6 scores and this difference increased with the dose.
The third question also aims to assess nasal discomfort in
a general manner to include nasal dryness, pain, sores and
epistaxis. The mean post radioiodine treatment RAI-6 scores
regarding nasal discomfort were also significantly higher than
the mean RAI-6 scores before radioiodine treatment and this
difference increased with the dose.
Ocular et nasal discomfort appear to be highly rated in
our patient’s group after radioiodine therapy. However, only
few studies describe ocular (13, 17) and nasal side effects
of radioiodine therapy (16, 17) which may result into an
underestimated rate of those complications.
The fourth and fifth questions aim to assess sialadenitis
symptoms by evaluation itching and swelling of the salivary
glands. The mean post radioiodine treatment RAI-6 scores
regarding those two items was significantly higher than before
TABLE 4 | Pre- and post-operative mean RAI-6 scores in patients who received
<or = 30 mCi.
Patients treated with











Q4 + Q5 0.2 0.54
Q6 0.1 1.2
TABLE 5 | Pre- and post-operative mean RAI-6 scores in patients who received
100 mCi.
Patients treated with











Q4 + Q5 0.1 0.5
Q6 0.1 1
TABLE 6 | Pre- and post-operative mean RAI-6 scores in patients who received
200–300 mCi.
Patients treated with











Q4 + Q5 0 2.3
Q6 0 5.3
treatment and this difference also increased with the radioiodine
dose. Our results correlate with Dingle et al.who determined the
prevalence of sialadenitis in patients treated with radioiodine for
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TABLE 7 | Mean RAI-6 scores in healthy participants.




Q4 + Q5 0
Q6 0.28
thyroid cancer using a 14 items self-administered questionnaire
(15) and concluded that the prevalence of sialadenitis was 26% for
patients who received between 100 and 200 mCi of radioiodine
and 43% for patients who were treated with over 200 mCi of
radioiodine. It is interesting to notice that sialadenitis did not
occur in patients who received <100 mCi of radioiodine. The
overall reported prevalence of sialadenitis following radioiodine
therapy varies from 2 to 67% in the literature (5), which would
imply an underestimated rate from many studies.
The last question evaluates the adverse effects of radioiodine
therapy on the quality of life of patients, which was rarely assessed
in previous studies. Dingle et al.evaluated the quality of life
with the University of Washington Quality of Life Questionnaire
(UW-QOL), and the Xerostomia-Related Quality of Life Scale
(Xe QOLS) (15), however other studies did not include direct
quality of life items (18). Bhayani et al.used a standard quality of
life (QOL) questionnaire and reported durable improvement in
symptoms after sialendoscopy (19). Due to the high survival rate,
and the likelihood of long-term complications after radioiodine
therapy, QOL needs to be evaluated in clinical practise (23).
Indeed, QOL is an important indicator to identify patients
requiring further care. In our study QOL was affected after
radioiodine treatment, especially with doses over or equal to
200 mCi.
The mean age of our patients was 56.2 years with a female
predilection (61.1%), which is in accordance with the previous
studies (24–26). Hollingsworth et al., showed that increased age
and female gender might be risk factors for radioiodine induced
salivary gland damage in thyroid cancer patients (21). Statistical
analysis of our study data demonstrated that a worse score on
the RAI-6 questionnaire does correlated with the radioiodine
dose given. Our study results are comparable with the studies
by Almeida et al. (14), Krcalova et al. (27), and Fard-Esfahani et
al. (28). The study by Almeida et al. showed that doses higher
than 150 mCi have more side effects on salivary glands (13).
Krcalova et al.concluded that RAI therapy up to 5.55 GBq (150
mCi) does not substantially decrease saliva production (27).
Fard-Esfahani et al. suggested that RAIS is more frequent in
differentiated thyroid cancer patients, with the higher dose of
100 mCi, compared to patients treated for hyperthyroidism with
doses <30 mCi (28).
Regarding healthy participants, none of them presented with
sialadenitis symptoms, however some of them experienced low
severity xerostomia, ocular and nasal discomfort symptoms
which slightly affected their QOL. It is therefore interesting to
notice that even healthy volunteers who do not present any risk
factors still may present oral dryness, ocular and nasal discomfort
from unknown aetiologies.
The purpose of the RAI is to be a screening test which aims
to be quickly completed. If the RAI shows any symptoms, the
recently developed MSGS questionnaire should be completed
to assess more precisely symptoms regarding salivary glands, as
well as clinical and/or radiological complementary investigations
adapted to every patient at the discretion of the clinician.
The RAI-6 questionnaire evaluates symptoms using a visual
analogue scale (VAS) system considered as a gold standard for the
assessment of clinical symptoms (29). The mean time necessary
to complete the RAI-6 questionnaire was 2min for patients and
49 s for healthy volunteers which makes it little time consuming.
None of the previous reports on questionnaires regarding the
complications of radioiodine therapy assessed the time needed
for their completion. However, most of these questionnaires had
more items than the present one; Choi et al. (16) and Jonklaas et
al. (17) used questionnaires that comprised 15 to 21 items, which
is in our opinion not appropriate for a screening score which aims
to be rapidly completed. Our questionnaire is designed to focus
on the most salient and subjective aspects, using only six easily
understandable and clinically relevant questions, covering the
most common complications of radioiodine therapy, and their
impact on the quality of life. At the same time, this questionnaire
does not impose a burden on patients or clinicians, due to its
short format.
The limitations of our study are the small sample size and
the retrospective evaluation of the patients who underwent
radioiodine therapy. In fact, patients who underwent radioiodine
therapy were asked to complete the RAI-6 questionnaire 3.6
years after the end of their treatment and to estimate if
any eventual symptoms were also present before radioiodine
treatment. A prospective study including patients who complete
the RAI-6 questionnaire before and after radioiodine therapy at
specific timelines would allow a more accurate understanding of
radioiodine adverse effects.
CONCLUSION
This preliminary study highlights the advantages of the newly
developed RAI-6 questionnaire to access complications of
radioiodine therapy. Our validation results indicate that the RAI-
6 questionnaire manages to quickly and concisely identify the
main complications of RAI therapy: sialadenitis, xerostomia,
ocular, and nasal discomfort. We also found that radioiodine-
induced complications have a significant impact on the quality
of life.
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